MX2014012271A - Conjugados bis-polimericos de lipido y peptido y sus nanoparticulas. - Google Patents

Conjugados bis-polimericos de lipido y peptido y sus nanoparticulas.

Info

Publication number
MX2014012271A
MX2014012271A MX2014012271A MX2014012271A MX2014012271A MX 2014012271 A MX2014012271 A MX 2014012271A MX 2014012271 A MX2014012271 A MX 2014012271A MX 2014012271 A MX2014012271 A MX 2014012271A MX 2014012271 A MX2014012271 A MX 2014012271A
Authority
MX
Mexico
Prior art keywords
conjugates
bis
nanoparticles
peptide conjugates
polymer lipid
Prior art date
Application number
MX2014012271A
Other languages
English (en)
Spanish (es)
Inventor
Ting Xu
He Dong
Jessica Shu
Nikhil Dube
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of MX2014012271A publication Critical patent/MX2014012271A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
MX2014012271A 2012-04-10 2013-04-10 Conjugados bis-polimericos de lipido y peptido y sus nanoparticulas. MX2014012271A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261622330P 2012-04-10 2012-04-10
US201261668923P 2012-07-06 2012-07-06
PCT/US2013/035924 WO2013155152A1 (en) 2012-04-10 2013-04-10 Bis-polymer lipid-peptide conjugates and nanoparticles thereof

Publications (1)

Publication Number Publication Date
MX2014012271A true MX2014012271A (es) 2015-05-11

Family

ID=49328119

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014012271A MX2014012271A (es) 2012-04-10 2013-04-10 Conjugados bis-polimericos de lipido y peptido y sus nanoparticulas.

Country Status (11)

Country Link
EP (1) EP2841083B1 (https=)
JP (2) JP6426600B2 (https=)
KR (1) KR20140143838A (https=)
CN (1) CN104379158A (https=)
AU (1) AU2013245989B2 (https=)
CA (1) CA2869984C (https=)
IL (1) IL235167A0 (https=)
IN (1) IN2014DN08781A (https=)
MX (1) MX2014012271A (https=)
RU (1) RU2014144945A (https=)
WO (1) WO2013155152A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9949927B2 (en) 2012-04-10 2018-04-24 The Regents Of The University Of California Bis-polymer lipid-peptide conjugates and nanoparticles thereof
JP6742982B2 (ja) * 2015-02-23 2020-08-19 日本化薬株式会社 生理活性物質結合ブロック共重合体
WO2017059338A1 (en) * 2015-10-02 2017-04-06 Cornell University Enzyme-responsive peptide nanofiber compositions and uses thereof
WO2020077170A1 (en) * 2018-10-12 2020-04-16 University Of Pittsburgh- Of The Commonwealth System Of Higher Education Small polymeric carriers for delivery of agents
CN119497732A (zh) * 2023-06-19 2025-02-21 华南理工大学 基于序列固定聚赖氨酸的pH敏感膜裂解材料及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999061066A2 (en) 1998-05-27 1999-12-02 Avigen, Inc. Convection-enhanced delivery of aav vectors
AU2002325120A1 (en) * 2001-09-10 2003-03-24 Celator Technologies Inc. Unilamellar vesicles stabilized with short chain hydrophilic polymers
WO2009059450A1 (en) * 2007-11-05 2009-05-14 Shanghai Jiaotong University Peptide ligand directed drug delivery
CA2724408A1 (en) * 2008-05-19 2009-11-26 The University Of North Carolina At Chapel Hill Methods and compositions comprising novel cationic lipids
EP2414278B1 (en) * 2009-04-03 2019-11-27 University Of Houston Metal nanoparticles functionalized with rationally designed coatings
WO2011066684A1 (zh) * 2009-12-03 2011-06-09 江苏恒瑞医药股份有限公司 伊立替康或盐酸伊立替康脂质体及其制备方法
EP2545072B1 (en) * 2010-03-12 2017-11-22 The Regents of The University of California Lipid-peptide-polymer conjugates and nanoparticles thereof

Also Published As

Publication number Publication date
JP6426600B2 (ja) 2018-11-21
EP2841083A1 (en) 2015-03-04
CA2869984C (en) 2021-08-17
JP2015520126A (ja) 2015-07-16
EP2841083B1 (en) 2020-08-05
CN104379158A (zh) 2015-02-25
WO2013155152A1 (en) 2013-10-17
KR20140143838A (ko) 2014-12-17
AU2013245989B2 (en) 2017-03-30
AU2013245989A1 (en) 2014-10-30
IL235167A0 (en) 2014-12-31
EP2841083A4 (en) 2016-07-13
RU2014144945A (ru) 2016-05-27
JP2018150327A (ja) 2018-09-27
IN2014DN08781A (https=) 2015-05-22
CA2869984A1 (en) 2013-10-17

Similar Documents

Publication Publication Date Title
MX2020000984A (es) Una composicion farmaceutica que comprende nanoparticulas hibridas amorfas estables, de al menos un inhibidor de proteina quinasa y al menos un componente estabilizador polimerico y formador de matriz.
WO2012116073A3 (en) Amphiphilic dendron-coils, micelles thereof and uses
IL238301A0 (en) Attachments for administering medicine containing unnatural amino acids and methods of use
IN2014DN00101A (https=)
PH12015500561A1 (en) Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same
HK1200089A1 (en) Biodegradable lipids for the delivery of active agents
EA201290482A1 (ru) Стабильные составы для лиофилизации терапевтических частиц
EP3003281A4 (en) Novel core-shell nanoparticles for oral drug delivery
EP3628335C0 (en) LIPID NANOPARTICLES FOR DELIVERY OF MRNA INTO THE LUNGS
SG10201804552WA (en) Nanoparticle compositions, formulations thereof, and uses therefor
EP3033113A4 (en) A novel plga-modified polyethylenimine self-assembly nanotechnology for nucleic acid and drug delivery
EP3065722A4 (en) Nucleic acid nanostructures for in vivo agent delivery
MY168297A (en) Cytotoxic Peptides and Antibody Drug Conjugates Thereof
MX350589B (es) Copolimeros funcionales pla-peg, las nanoparticulas de los mismos, su preparacion y su uso para la administracion dirigida de farmacos e imagenologia.
WO2013028942A8 (en) Targeting microbubbles
WO2014057432A3 (en) Multicomponent lipid nanoparticles and processes for the preparation thereof
MX348823B (es) Formulaciones estables de linaclotida.
WO2012174158A3 (en) Administration of benzodiazepine
MX2014002062A (es) Nanoparticulas de peptido y usos de las mismas.
MX2015010083A (es) Nanoparticulas biodegradables y clinicamente compatibles como portadores para administracion de farmacos.
IL227665A0 (en) Nanoparticle transfer systems, preparation and uses
MX2014012271A (es) Conjugados bis-polimericos de lipido y peptido y sus nanoparticulas.
EP3065783A4 (en) Dual molecular delivery of oligonucleotides and peptide containing conjugates
MX371349B (es) Una composicion farmaceutica que comprende nanoparticulas hibridas amorfas estables, de al menos un inhibidor de proteina quinasa y al menos un componente estabilizador polimerico y formador de matriz.
WO2011130716A3 (en) A nanostructures containing vitamin b12 for facilitated delivery of drugs across biological barriers